Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Research & Development (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of Research & Development readings, the most recent being $2.7 million for Q1 2026.

  • On a quarterly basis, Research & Development fell 31.54% to $2.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $11.5 million, a 17.71% decrease, with the full-year FY2025 number at $12.7 million, changed 0.48% from a year prior.
  • Research & Development hit $2.7 million in Q1 2026 for Catalyst Pharmaceuticals, up from $1.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $83.7 million in Q3 2023 to a low of $1.8 million in Q4 2025.
  • Median Research & Development over the past 5 years was $3.6 million (2023), compared with a mean of $8.3 million.
  • Biggest five-year swings in Research & Development: skyrocketed 906.76% in 2023 and later plummeted 96.07% in 2024.
  • Catalyst Pharmaceuticals' Research & Development stood at $4.1 million in 2022, then tumbled by 51.82% to $2.0 million in 2023, then skyrocketed by 92.6% to $3.8 million in 2024, then plummeted by 52.42% to $1.8 million in 2025, then skyrocketed by 47.26% to $2.7 million in 2026.
  • The last three reported values for Research & Development were $2.7 million (Q1 2026), $1.8 million (Q4 2025), and $2.7 million (Q3 2025) per Business Quant data.